<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165685</url>
  </required_header>
  <id_info>
    <org_study_id>KES524-J081-161</org_study_id>
    <nct_id>NCT00165685</nct_id>
  </id_info>
  <brief_title>A Comparative Study of KES524 in Patients With Obesity Disease</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of KES524 in patients with obesity (visceral fat&#xD;
      obesity with type 2 diabetes and dyslipidemia), a 52-week, double-blind, placebo-controlled&#xD;
      comparative study is conducted. This study aims to examine superiority of KES524 to placebo&#xD;
      by employing change and percent change in body weight (primary endpoints) and changes in&#xD;
      proportion of subjects achieving ≧ 5% weight reduction, BMI, waist circumference, visceral&#xD;
      fat area, subcutaneous fat area, V/S ratio by abdominal CT scan, HbA1c, TG and HDL-C&#xD;
      (secondary endpoints).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change and percent change in body weight</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving ≧5% weight reduction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral fat area, subcutaneous fat area, and V/S ratio by abdominal CT scan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and percent change in fasting serum lipids (TG, HDL-C)</measure>
  </secondary_outcome>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sibutramine Hydrochloride Monohydrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ≧25 kg/m2 of BMI at the start of the observation period&#xD;
&#xD;
          -  Patients with visceral fat area ≧100 cm2 measured with abdominal CT scan&#xD;
&#xD;
          -  Patients with the following two health impairments:&#xD;
&#xD;
               1. Patients with previously diagnosed type 2 diabetes and HbA1c between ≧6.1% and&#xD;
                  &lt;9.0% at the start of observation period&#xD;
&#xD;
               2. Patients with ≧150 mg/dL of triglyceride (TG), and/or &lt;40 mg/dL of high-density&#xD;
                  lipoprotein cholesterol (HDL-C) for serum lipid parameters as dyslipidemic index&#xD;
                  at the start of the observation period&#xD;
&#xD;
          -  Patients continuously receiving diet therapy for 8 weeks or longer before the start of&#xD;
             the observation period&#xD;
&#xD;
          -  Patients not receiving antidiabetic (12 weeks), antihyperlipidemics (4 weeks) and/or&#xD;
             antihypertensive (4 weeks) drugs. If used, those who have received a consistent dosage&#xD;
             and administration beginning more than 4 weeks (more than 12 weeks for antidiabetics)&#xD;
             before the start of the observation period&#xD;
&#xD;
          -  Patients with ambulatory treatment aged between ≧20 years and &lt;65 years at the time of&#xD;
             obtaining informed consent&#xD;
&#xD;
          -  Patients who are given full explanation about the study objective and contents and can&#xD;
             give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with pulse rate of ≧100/min during the observation period&#xD;
&#xD;
          -  Patients with systolic blood pressure of ≧160 mmHg and/or with diastolic blood&#xD;
             pressure of ≧100 mmHg during the observation period&#xD;
&#xD;
          -  Patients with body weight loss of ≧3% as compared to that at the start of the&#xD;
             observation period, or body mass index (BMI) that is reduced to &lt;25 kg/m2 during the&#xD;
             observation period&#xD;
&#xD;
          -  Patients who have received insulin within 12 weeks before the start of the observation&#xD;
             period&#xD;
&#xD;
          -  Patients with present illness or past history of severe eating disorder (e.g.,&#xD;
             anorexia nervosa or bulimia nervosa)&#xD;
&#xD;
          -  Patients with present illness or past history of drug allergy or severe allergic&#xD;
             disease(s)&#xD;
&#xD;
          -  Patients with present illness or past history of the following disorders:&#xD;
&#xD;
          -  Coronary artery disease (myocardial infarction, angina), heart failure&#xD;
&#xD;
          -  Serious diseases such as cardiovascular (severe tachycardiac heart failure), renal&#xD;
             (renal failure), hepatic (severe hepatitis, cirrhosis), pancreatic (severe&#xD;
             pancreatitis), psychotic (severe depression, schizophrenia, alcohol addict, drug&#xD;
             addict) disorders&#xD;
&#xD;
          -  Pregnant or lactating women, or women who intend to become pregnant during the study&#xD;
             period&#xD;
&#xD;
          -  Patients who previously participated in and were treated in another clinical study of&#xD;
             KES524&#xD;
&#xD;
          -  Patients who have received another study drug within 24 weeks before starting&#xD;
             observation period of this study&#xD;
&#xD;
          -  Patients who are judged to be ineligible for study entry by the investigator or&#xD;
             subinvestigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Takeuchi</last_name>
    <role>Study Director</role>
    <affiliation>Development Clinical Research Dept., Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <state>Chiba Prefecture</state>
        <zip>260-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba Prefecture</state>
        <zip>277-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakura</city>
        <state>Chiba Prefecture</state>
        <zip>285-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima</city>
        <state>Fukushima Prefecture</state>
        <zip>960-1247</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koriyama</city>
        <state>Fukushima Prefecture</state>
        <zip>963-8022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma Prefecture</state>
        <zip>371-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachiota</city>
        <state>Ibaraki Prefecture</state>
        <zip>313-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mito</city>
        <state>Ibaraki Prefecture</state>
        <zip>311-4153</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naka</city>
        <state>Ibaraki Prefecture</state>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki Prefecture</state>
        <zip>300-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki Prefecture</state>
        <zip>305-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi Prefecture</state>
        <zip>980-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi Prefecture</state>
        <zip>980-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>193-0944</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>January 28, 2010</last_update_submitted>
  <last_update_submitted_qc>January 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

